Potential for Nuclear Medicine Therapy for Glioblastoma Treatment

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment

Glioblastoma is the most common malignant adult brain tumor and has a very poor patient prognosis. The mean survival for highly proliferative glioblastoma is only 10 to 14 months despite an aggressive current therapeutic approach known as Stupp’s protocol, which consists of debulking surgery followe...

Full description

Bibliographic Details
Main Authors: Clément Bailly, Aurelien Vidal, Coralie Bonnemaire, Françoise Kraeber-Bodéré, Michel Chérel, Amandine Pallardy, Caroline Rousseau, Emmanuel Garcion, Franck Lacoeuille, François Hindré, Samuel Valable, Myriam Bernaudin, Caroline Bodet-Milin, Mickaël Bourgeois
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Pharmacology
Subjects:
glioblastoma
nuclear medicine
cancer
radioimmunotherapy (RIT)
peptide receptor radiotherapy (PRRT)
radionanoparticles
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00772/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00772/full

Similar Items